Universitaetsklinikum Schleswig-Holstein AöR
Universitaetsklinikum Schleswig-Holstein AöR is recorded as a service provider in 10 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 10 of 10 trials · Latest update first
A Prospective, Open-Label, Multicenter, Randomized, Phase 3 Trial of Acalabrutinib, Obinutuzumab and Venetoclax (GAVe) Compared to Obinutuzumab and Venetoclax (GVe) in Previously Untreated Patients with High Risk Chronic Lymphocytic Leukemia (CLL): The CLL16-TRIAL OF THE GCLLSG
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/MOIRAI)
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
Glofitamab Combined With Pirtobrutinib in Relapsed/Refractory Patients with Mantle Cell Lymphoma Followed by an Extension in Treatment Naïve Patients (PLATO)
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Face and Neck Atopic Dermatitis
Sponsor Almirall S.A.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with DLBCL-type Richter Transformation
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequent Maintenance with Elotuzumab and Lenalidomide versus Single-Agent Lenalidomide. A phase III study by DSMM (Deutsche Studiengruppe Multiples Myelom)
Sponsor Universitaetsklinikum Wuerzburg AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND]
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
Integrated exploratory phase 1/2a study, double-blind, randomized, controlled to evaluate the Safety and Efficacy of FTP-002 / FTP-501 combination in the treatment of glabellar lines
Sponsor Fastox Pharma S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in patients with relapsed/refractory CLL - (CLL2-BZAG)
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Universitaetsklinikum Schleswig-Holstein AöR?
The 2026-10-09 snapshot links Universitaetsklinikum Schleswig-Holstein AöR to 10 distinct CTIS trials. Recorded services include Laboratory services, Data management, Diagnostik Durchflusszytometrie / Next Generation Sequencing, Long-term sample storage (ctDNA and MRD), among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Universitaetsklinikum Schleswig-Holstein AöR?
The most frequently recorded therapeutic areas are Haematological Malignancies, Dermatology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Universitaetsklinikum Schleswig-Holstein AöR conducted?
The linked trials record locations in 21 countries, including Germany, Austria, Denmark, Spain, France. These are trial locations, not confirmed office locations or countries where Universitaetsklinikum Schleswig-Holstein AöR delivered services.
What can this page tell me about Universitaetsklinikum Schleswig-Holstein AöR's trial experience?
Browse 10 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Universitaetsklinikum Schleswig-Holstein AöR. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Universitaetsklinikum Schleswig-Holstein AöR